الفهرس 
Hepatitis C virus
TransmissionOnly 14 pages are availabe for public view
 |  | from | 148 |  |  |
| | | from | 148 | | |
Abstract
Hepatitis C virus (HCV) infection is strongly
associated with chronic kidney disease (CKD). It is an
independent risk factor for developing CKD and significantly
increases morbidity and mortality in CKD patients. Recently,
there have been major advancements in the treatment of
HCV with the development of new direct‐ acting antivirals
(DAAs). Treatment with newer direct-acting antiviral (DAA)
regimens in patients with CKD is showing conflicting results
as regards safety and efficacy.Despite recent advances, little
is known about the effect of HCV treatment with DAAs on
short and long-term kidney function. Whether or not the
CKD progression can be slowed by HCV treatment has not
been established. Therefore, we aimed to evaluate the impact
of those two different DAA regimens on HCV infected
patients with chronic kidney disease.
100 CKD patients were included , stages 3-4, receiving
treatment for HCV at MASRI (faculty of Medicine Ain
Shams University Research Institute), with two different
DAAs regimens ( Sofosbuvir/ Daclatasvir with or without
Ribavirin and Ombitasvir/Paritaprevir /Ritonavir
(OMV/PTV/RTV) with Ribavirin), completed over six
months follow up. Serum creatinine, eGFR (estimated
glomerular filtration rate), and proteinuria were followed
Summary
116
during and after treatment. Sustained virological response
(SVR) was achieved in all patients. Improvement of eGFR
(8-15 ml/min/1.73 m2) and proteinuria was found in both
study groups. AKI (acute kidney injury) was uncommon; it
occurred in three (3%) patients, out of them, two patients
showed complete recovery. Adverse events were common
(43%), but serious adverse events were uncommon (2%).